-
Product Insights
Tempest Wind Farm
Tempest Wind Farm is an Onshore Wind project located in Alberta, Canada. The project is owned and being developed by TransAlta Corp. The project is at the permitting stage. Empower your strategies with our Tempest Wind Farm report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report may...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – CD33 NKE in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CD33 NKE in Relapsed Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CD33 NKE in Relapsed Multiple Myeloma Drug Details: CD33 NKE...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TPST-1495 in Endometrial Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TPST-1495 in Endometrial Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TPST-1495 in Endometrial Cancer Drug Details: TPST-1495 is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – (Favezelimab + Pembrolizumab) in Metastatic Renal Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Favezelimab + Pembrolizumab) in Metastatic Renal Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Favezelimab + Pembrolizumab) in Metastatic Renal Cell Carcinoma...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OPN-2853 in Myelofibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OPN-2853 in Myelofibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. OPN-2853 in Myelofibrosis Drug Details: PLX-2853 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lutetium Lu 177 Vipivotide Tetraxetan in Hormone-Sensitive Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lutetium Lu 177 Vipivotide Tetraxetan in Hormone-Sensitive Prostate Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lutetium Lu 177 Vipivotide Tetraxetan in Hormone-Sensitive...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Docetaxel in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Docetaxel in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Docetaxel in Non Muscle Invasive...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Aldesleukin in Amyotrophic Lateral Sclerosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Aldesleukin in Amyotrophic Lateral Sclerosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Aldesleukin in Amyotrophic Lateral Sclerosis Drug Details: Aldesleukin (Proleukin) is an...
-
Product Insights
Adrenal Gland Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Adrenal Gland Cancer - Drugs In Development, 2023’, provides an overview of the Adrenal Gland Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Adrenal Gland Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Drugs In Development, 2023
Global Markets Direct’s, ‘Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Drugs In Development, 2023’, provides an overview of the Adrenocortical Carcinoma (Adrenal Cortex Cancer) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...